Ellevest Inc. Reduces Holdings in GSK plc (NYSE:GSK)

Ellevest Inc. lessened its position in shares of GSK plc (NYSE:GSK) by 27.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 13,798 shares of the pharmaceutical company’s stock after selling 5,301 shares during the quarter. Ellevest Inc.’s holdings in GSK were worth $467,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Franklin Resources Inc. lifted its stake in shares of GSK by 8.6% in the 3rd quarter. Franklin Resources Inc. now owns 235,348 shares of the pharmaceutical company’s stock valued at $9,052,000 after purchasing an additional 18,539 shares during the last quarter. ST Germain D J Co. Inc. lifted its position in GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 522 shares during the last quarter. Green Alpha Advisors LLC boosted its stake in GSK by 17.7% during the fourth quarter. Green Alpha Advisors LLC now owns 27,316 shares of the pharmaceutical company’s stock worth $924,000 after buying an additional 4,107 shares during the period. Fiduciary Alliance LLC acquired a new stake in shares of GSK during the fourth quarter valued at about $390,000. Finally, Brookstone Capital Management raised its stake in shares of GSK by 19.8% in the 4th quarter. Brookstone Capital Management now owns 31,701 shares of the pharmaceutical company’s stock valued at $1,072,000 after acquiring an additional 5,244 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Trading Down 0.7 %

Shares of NYSE:GSK opened at $36.63 on Friday. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.93. The company’s 50 day moving average is $37.65 and its two-hundred day moving average is $36.00. The company has a market cap of $75.58 billion, a PE ratio of 23.04, a P/E/G ratio of 1.12 and a beta of 0.51. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.05. The company had revenue of $10.06 billion for the quarter, compared to analysts’ expectations of $7.52 billion. GSK had a return on equity of 48.59% and a net margin of 8.13%. GSK’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period last year, the firm earned $0.43 earnings per share. Equities analysts predict that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be issued a $0.4216 dividend. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, May 16th. This represents a $1.69 annualized dividend and a dividend yield of 4.60%. GSK’s dividend payout ratio is presently 86.60%.

Analyst Ratings Changes

Several analysts recently weighed in on GSK shares. BNP Paribas started coverage on shares of GSK in a report on Tuesday, April 15th. They issued a “neutral” rating and a $35.25 target price for the company. Hsbc Global Res upgraded GSK to a “strong sell” rating in a report on Monday, April 28th. Morgan Stanley began coverage on GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Finally, StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $40.58.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.